NCT06587165

Quantifying New Heart Muscle Cells

A Pilot Study for Quantifying New Heart Muscle Cells

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Weill Medical College of Cornell University · Academic / Other
• Sex: All
• Age: 30 Days – 1 Year
• Healthy volunteers: Not accepted

Summary

Regenerative therapies could provide new ways of treating heart failure. Unlike many organs in the human body, such as the skin and the GI tract, the ability to regenerate heart muscle decreases after birth, but the precise timing of this decrease and how this decrease is altered in heart disease are uncertain. The investigators will use an innovative approach to quantify cellular heart regeneration in pediatric patients, an appropriate population for determining this decline as well as the potential for reactivating heart muscle regeneration. The study has now been registered on ClinicalTrials.gov, despite its initiation on July 23, 2015, as registration was not mandated at the original study site, the University of Pittsburgh Medical Center. However, following the transfer of the study to Weill Cornell Medicine, adherence to institutional requirements necessitated its registration on ClinicalTrials.gov.

Conditions

• Tetralogy of Fallot With Pulmonary Stenosis
• Heart Failure

Interventions

Type	Name	Description
OTHER	N15-thymidine	50mg/kg (oral administration)

Timeline

• Start date: 2015-07-23
• Primary completion: 2027-03-01
• Completion: 2027-03-01
• First posted: 2024-09-19
• Last updated: 2025-07-28

Locations

1 site across 1 country: United States